Poignant piece in the NY Times magazine that highlights some of the flaws in our unsustainable health care non-system. This paragraph outlines the problem
After making more than 70 phone calls to 16 organizations over the past few weeks, I’m still not totally sure what I will owe for my Revlimid, a derivative of thalidomide that is keeping my multiple myeloma in check. The drug is extremely expensive — about $11,000 retail for a four-week supply, $132,000 a year, $524 a pill. Time Warner, my former employer, has covered me for years under its Supplementary Medicare Program, a plan for retirees that included a special Writers Guild benefit capping my out-of-pocket prescription costs at $1,000 a year. That out-of-pocket limit is scheduled to expire on Jan. 1. So what will my Revlimid cost me next year?
Medicynical note: Anyone believing our non-system is the best in the world should need such drugs. While drug companies spend a great deal to develop medications, their costs are inflated and overstated. Efficiency is simply not on their agenda. Nor is patient well being, access or for that matter outcomes.
It’s the money stupid! Charging more than twice the median U.S. income for a single drug that patients in life-threatening situation, any single drug, is simple blackmail. It reflects an industry and economy gone mad.